Intranasal administration of dry powder anthrax vaccine provides protection against lethal aerosol spore challenge

Human Vaccines

Volumn 3, Issue 3, 2007, Pages 90-93

  Huang, Joanne ^a   Mikszta, John A ^a   Ferriter, Matthew S ^a   Jiang, Ge ^a,c   Haivey, Noel G ^a   Dyas, Beverly ^b   Roy, Chad J ^b,d   Ulrich, Robert G ^b   Sullivan, Vincent J ^a  

^a BD Technologies   (United States)

^b UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^c AMGEN INC   (United States)

^d TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

Author keywords

Anthrax; Biodefense; Immune response; Intranasal; Protective antigen; Spray freeze dried powder; Vaccine

Indexed keywords

ANTHRAX VACCINE; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY;

AEROSOL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTHRAX; ARTICLE; BACILLUS ANTHRACIS; CONTROLLED STUDY; DRUG FORMULATION; DRY POWDER; EVALUATION; NONHUMAN; RABBIT;

EID: 34248144460     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.3.3.4011     Document Type: Article

References (23)

1. Ashford DA, Perkins B, Rotz LD. Use of anthrax vaccine in the united scares: Centers for disease control and prevention morbidity and mortality weekly report. 49(RR15):1-20.
2. Griffith KS, Mead P, Armstrong GL, Painter J, Kelley KA, Hoffmaster AR, Mayo D, Barden D, Ridzon R, Parashar U, Teshale EH, Williams J, Noviello S, Perz JF, Mast EE, Swerdlow DL, Hadler JL. Bioterrorism-relared inhalational anthrax in an elderly woman, Connecticut, 2001. Emerg Infect Dis 2003; 9:681-8.
3. Jernigan JA, Stephens DS, Ashford DA, Omenaca C, Topiel MS, Galbraith M, Tapper M, Fisk TL, Zaki S, Popovic T, Meyer RF, Quinn CP, Harper SA, Fridkin SK, Sejvar JJ, Shepard CW, McConnell M, Guarner J, Shleh WJ, Malecki JM, Gerberding JL, Hughes JM, Perkins BA. Bioterrorism-related inhalational anthrax: The first 10 cases reported in the United States. Emerg Infect Dis 2001; 7:933-44.
4. Pittman PR, Kim-Ahn G, Pifat DY, Coonan K, Gibbs P, Little S, Pace-Templeton JG, Myers R, Parker GW, Friedlander AM. Anthrax vaccine: Immunogenicity and safety of a dose-reduction, route-change comparison study in humans. Vaccine 2002; 20:1412-20.
5. Huang J, Garmise RJ, Crowder TM, Mar K, Hwang CR, Hickey AJ, Mikszta JA, Sullivan VJ. A novel dry powder influenza vaccine and intranasal delivery technology. Induction of systemic and mucosal immune responses in rats. Vaccine 2004; 23:794-801.
6. Neutra MR, Kozlowski PA. Mucosal vaccines: The promise and the challenge. Nat Rev Immunol 2006; 6:148-58.
7. Sullivan VJ, Mikszta JA, Laurent P, Huang J, Ford B. Non-invasive delivery technologies: Respiratory delivery of vaccines. Expert Opin Drug Deliv 2006; 3:87-95.
8. Boyaka PN, Tafaro A, Fischer R, Leppla SH, Fujihashi K, McGhee JR Effective mucosal immunity to anthrax: Neutralizing antibodies and Th cell responses following nasal immunization with protective antigen. J Immunol 2003; 170:5636-43.
9. Gaur R, Gupta PK, Banerjea AC, Singh Y. Effect of nasal immunization with protective antigen of Bacillus anthracis on protective immune response against anthrax toxin. Vaccine 2002; 20:2836-9.
10. Sloat BR, Cui Z. Strong mucosal and systemic immunities induced by nasal immunization with anthrax protective antigen protein incorporated in liposome-protamine-DNA particles. Pharm Res 2006; 23:262-9.
11. Becker Y. CpG ODNs treatments of HIV-1 infected patients may cause the decline of transmission in high risk populations - A review, hypothesis and implications. Virus Genes 2005; 30:251-66.
12. Klinman DM. CpG DNA as a vaccine adjuvant. Expert Rev Vaccines 2003; 2:305-15.
13. Halperin SA, Van Nest G, Smith B, Abtahi S, Whiley H, Eiden JJ. A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen coadministered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine 2003; 21:2461-7.
14. Flick-Smith HC, Eyles JE, Hebdon R, Waters EL, Beedham RJ, Stagg TJ, Miller J, Alpar HO, Baillie LW, Williamson ED. Mucosal or parenteral administration of microsphere-associated Bacillus anthracis protective antigen protects against anthrax infection in mice. Infect Immun 2002; 70:2022-8.
15. Mikszta JA, Sullivan VJ, Dean C, Waterston AM, Alarcon JB, Dekker IIIrd JP, Brittingham JM, Huang J, Hwang CR, Ferriter M, Jiang G, Mar K, Saikh KU, Stiles BG, Roy CJ, Ulrich RG, Harvey NG. Protective immunization against inhalational anthrax: A comparison of minimally invasive delivery platforms. J Infect Dis 2005; 191:278-88.
16. Jiang G, Joshi SB, Peek LJ, Brandau DT, Huang J, Ferriter MS, Woodley WD, Ford BM, Mar KD, Mikszta JA, Hwang CR, Ulrich R, Harvey NG, Middaugh CR, Sullivan VJ. Anthrax vaccine powder formulations for nasal mucosal delivery. J Pharm Sci 2006; 95:80-96.
17. Anderson J, Fishbourne E, Corteyn A, Donaldson AI. Protection of catde against rinderpest by intranasal immunisation with a dry powder tissue culture vaccine. Vaccine 2000; 19:840-3.
18. Ilium L, Jabbal-Gill I, Hinchcliffe M, Fisher AN, Davis SS. Chitosan as a novel nasal delivery system for vaccines. Adv Drug Deliv Rev 2001; 51:81-96.
19. Soane RJ, Hinchcliffe M, Davis SS, Illum L. Clearance characteristics of chitosan based formulations in the sheep nasal cavity. Int J Pharm 2001; 217:183-91.
20. LiCalsi C, Christensen T, Bennett JV, Phillips E, Witham C. Dry powder inhalation as a potential delivery method for vaccines. Vaccine 1999; 17:1796-803.
21. LiCalsi C, Maniaci MJ, Christensen T, Phillips E, Ward GH, Witham C. A powder formulation of measles vaccine for aerosol delivery. Vaccine 2001; 19:2629-36.
22. de Swart RL, LiCalsi C, Quirk AV, van Amerongen G, Nodelman V, Alcock R, Yuksel S, Ward GH, Hardy JG, Vos H, Witham CL, Grainger CI, Kuiken T, Greenspan BJ, Gard TG, Osterhaus AD. Measles vaccination of macaques by dry powder inhalation. Vaccine 2006, (doi: 10.1016/j.vaccine.2006.10.019).
23. Mikszta JA, Dekker JP, Harvey NG, Dean CH, Brittingham JM, Huang J, Sullivan VJ, Dyas B, Roy CP, Ulrich RG. Micro needle-based intradermal delivery of the anthrax recombinant Protective Antigen vaccine. Infect Immun 2006; 74:6806-10.